MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

Quidel Corp

Uždarymo kaina

30.45 3.68

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

29.38

Max

31.33

Pagrindiniai rodikliai

By Trading Economics

Darbuotojai

6,600

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-12.92% downside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

277M

1.9B

Ankstesnė atidarymo kaina

26.77

Ankstesnė uždarymo kaina

30.45

Quidel Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-22 21:55; UTC

Uždarbis

Capital One Financial Posts Higher 4Q Profit As Lending Increases

2026-01-22 23:52; UTC

Uždarbis

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

2026-01-22 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

2026-01-22 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Profit-Taking -- Market Talk

2026-01-22 23:40; UTC

Rinkos pokalbiai

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

2026-01-22 23:30; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-22 23:30; UTC

Rinkos pokalbiai

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

2026-01-22 22:37; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

2026-01-22 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

2026-01-22 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-01-22 21:44; UTC

Uždarbis

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

2026-01-22 21:32; UTC

Įsigijimai, susijungimai, perėmimai

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

2026-01-22 21:31; UTC

Įsigijimai, susijungimai, perėmimai

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

2026-01-22 21:31; UTC

Įsigijimai, susijungimai, perėmimai

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

2026-01-22 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

2026-01-22 21:30; UTC

Uždarbis

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

2026-01-22 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Capital One To Acquire Brex >COF

2026-01-22 21:13; UTC

Uždarbis

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

2026-01-22 21:11; UTC

Uždarbis

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

2026-01-22 21:11; UTC

Uždarbis

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

2026-01-22 21:10; UTC

Uždarbis

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

2026-01-22 21:06; UTC

Uždarbis

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

2026-01-22 21:05; UTC

Uždarbis

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

2026-01-22 21:05; UTC

Uždarbis

Capital One 4Q Rev $15.58B >COF

2026-01-22 21:05; UTC

Uždarbis

Capital One 4Q EPS $3.26 >COF

2026-01-22 21:05; UTC

Uždarbis

Capital One 4Q Net Interest Margin 8.26% >COF

2026-01-22 21:05; UTC

Uždarbis

Capital One 4Q Net $2.13B >COF

2026-01-22 21:05; UTC

Uždarbis

Capital One 4Q Adj EPS $3.86 >COF

2026-01-22 21:05; UTC

Uždarbis

Capital One 4Q Net Charge-Offs $3.8B >COF

2026-01-22 21:05; UTC

Uždarbis

Intuitive Surgical 4Q EPS $2.21 >ISRG

Akcijų palyginimas

Kainos pokytis

Quidel Corp Prognozė

Kainos tikslas

By TipRanks

-12.92% į apačią

12 mėnesių prognozė

Vidutinis 28.5 USD  -12.92%

Aukščiausias 35 USD

Žemiausias 22 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Quidel Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

1

Pirkti

3

Laikyti

1

Parduoti

Finansinės naujienos

$

Apie bendrovę Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat